OPTICAL COHERENCE TOMOGRAPHY-BASED RANIBIZUMAB MONOTHERAPY FOR RETINAL ANGIOMATOUS PROLIFERATION IN KOREAN XXXX .

@entity1 @entity1940 @entity541 @entity2479 @entity1020
PURPOSE:: To evaluate the visual outcome of optical coherence tomography-based ranibizumab monotherapy in Korean @entity1 with @entity2479 and identify prognostic factors of visual outcome. METHODS:: A prospective single-arm clinical study of 31 @entity2479 @entity1 who underwent 3 consecutive monthly intravitreal ranibizumab injections was conducted. Additional treatment was given based on optical coherence tomography at monthly follow-ups over 24 months. RESULTS:: Best-corrected visual acuity improved from 48.7    19.3 to 56.3    19.1 letters at 24 months (P = 0.010). Total cumulative numbers of injection were 5.5    2.2 and 7.7    3.4 times at 12 and 24 months, respectively. Older age, larger @entity1940 size, and poor initial best-corrected visual acuity were associated with poor visual outcome. Final best-corrected visual acuity was significantly worse with Stage 3 disease (70.4    5.1, 62.3    11.6, 46.2    22.3 letters improved in each stage; P = 0.015). Among factors associated with poor visual outcome, only the stage of @entity2479 remained statistically significant on multiple linear regression analysis (P = 0.006). Although baseline best-corrected visual acuity was similar, Stage 3 @entity1 exhibited limited visual improvement despite anatomical improvement, and more recurrences requiring more injections. CONCLUSION:: @entity2479 may be successfully managed with ranibizumab monotherapy in Korean @entity1 , with the number of treatments required comparable to other forms of neovascular age-related @entity1020 . However, visual improvement was limited in late-stage @entity541 .
